Global biopharma mergers and acquisitions (M&A) are experiencing a sharp uptick in 2026, with dealmaking momentum putting the sector on track for its strongest year since the pre-pandemic peak seven years ago [1]. According to PitchBook data, biotech deals have amounted to $106 billion across 201 transactions so far this year [1]. If this pace continues, the industry could reach more than $250 billion in deal value by year-end, surpassing the previous peak in 2019 [1]. This surge follows a post-pandemic trough in 2022 and a softer 2024, where total deal value dropped to $114.8 billion, before rebounding to $209 billion in 2025 [1].
The uptick in M&A activity is driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's urgent need to bolster their pipelines as best-selling drugs lose exclusivity in the coming years [1]. Many pharmaceutical companies are also looking to China for innovative solutions [1]. Despite a deteriorating interest rate environment following the Iran war and inflationary impacts, dealmaking has remained robust, though the first half of the year was more conducive to deals than the current environment, according to Rajesh Kumar, Head of Life Sciences and Healthcare Equity Research at HSBC [1]. Kumar noted that pharma companies are "really buying stuff like it's going out of fashion" [1].
The majority of capital allocation is concentrated in strategic acquisitions and corporate add-ons, with drug discovery dominating the deal flow [1]. Nanna Lüneborg, general partner at Forbion, highlighted that pharma giants are primarily targeting "bolt-on" acquisitions in the $1 billion to $5 billion range, such as GSK's recent $2.2 billion acquisition of RAPT Therapeutics [1]. These smaller deals are easier to integrate and face fewer anti-competitive hurdles compared to mega-mergers in the $10 billion to $20 billion range [1]. The average deal value in 2026 has spiked to $527.3 million, up from $365 million in 2025 [1].
CONCLUSION
Biotech M&A activity is accelerating in 2026, with deal values and volumes on track to surpass previous records. Despite challenging macroeconomic conditions, strategic acquisitions are dominating, reflecting Big Pharma's urgent need to replenish pipelines. The market is responding positively to this surge, signaling high impact for the sector.